Responses

other Versions

PDF
Efficacy of Intravitreal bevacizumab for polypoidal choroidal vasculopathy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Bevacizumab for polypoidal vasculopathy should be evaluated in a cross cultural population
    • Shree K Kurup, Consultant Retina & Uveitis
    • Other Contributors:
      • Mehdi Ghajarnia

    Dear Editors

    We read with great interest, the illuminating article by Drs Gomi, Sawa and Tano. Our limited experience (4 Afro-American patients) with intravitreal bevacizumab (IVB) for polypoidal vasculopathy (PPV) has been more positive.

    We had reported the first success early this year in terms of lasting remission [1]. Furthermore, I enclose details on another patient who had PPV OU, in all likeliho...

    Show More
    Conflict of Interest:
    None declared.